Abbreviations
PBC, primary biliary cholangitis; PPAR α/δ, peroxisome proliferator-activated receptor alpha + delta
Reference
- IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024.
▼ This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
IQIRVO
Mechanism of action
IQIRVO provides a multi-targeted approach
While the exact mechanism by which IQIRVO exerts its therapeutic effects in patients with PBC is not fully understood, it is thought that PPAR-α and PPAR-δ are key regulators of bile acid homeostasis, inflammation and fibrosis.
